Judith Anne Shizuru is Director at Jasper Therapeutics, Inc. (JSPR). They have made 1 open-market trade across 1 company since 2025, most recently 2025-09-22.
CIK 0001883000
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $100K since 2025, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JSPR | 156,901 | $75K |
Shares reported on the most recent Form 4, priced at the 2025-09-24 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JSPR | BUY | 2025-09-22 | 2025-09-24 | $2.43 | $100K | -4.0% | -5.2% | -27.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.